Interstitial lung disease in South Africans with systemic sclerosis by Ashmore, Philippa
i 
 
 
 
INTERSTITIAL LUNG DISEASE IN SOUTH AFRICANS WITH 
SYSTEMIC SCLEROSIS 
 
Philippa Ashmore 
 
 
 
 
 
 
 
 
 
A research report submitted to the Faculty of Health Sciences, University of the 
Witwatersrand, in partial fulfilment of the requirements for the degree of Master of 
Medicine in the branch of Internal Medicine. 
Johannesburg, 2014
ii 
 
DECLARATION 
 
I, Philippa Ashmore declare that this research report is my own work.  It is being 
submitted for the degree of Master of Medicine in the University of the 
Witwatersrand, Johannesburg.  It has not been submitted before for any degree or 
examination at this or any other University. 
 
Signed: _____________________ 
 
Date:  _______ day of ___________________, 2014 
  
iii 
 
Dedicated to my son 
Drew Peter Ashmore 
  
iv 
 
PRESENTATIONS ARISING FROM THIS STUDY 
Poster presentation: 
Ashmore P, Tikly M, Wong M, Ickinger C.   Interstitial Lung Disease in South 
Africans with Systemic Sclerosis.  3rd Systemic Sclerosis World Congress, Rome 
2014. 
Oral presentation: 
Ashmore P, Tikly M, Wong M, Ickinger C.   Frequency And Predictors Of Interstitial 
Lung Disease In Systemic Sclerosis.  University of the Witwatersrand Faculty of 
Health Sciences Biennial Research Day and Postgraduate Expo. Johannesburg 
2014. 
 
  
v 
 
ABSTRACT 
BACKGROUND: Interstitial lung disease (ILD) is one of the leading causes of death 
in systemic sclerosis (SSc).   
PATIENTS AND METHODS: A retrospective review of case records, over 20 years, 
of SSc patients attending a tertiary Connective Tissue Diseases Clinic. Comparisons 
between ILD and non-ILD groups at presentation were performed in order to identify 
baseline associations and predictors of ILD. 
RESULTS: Of the 151 participants that met inclusion criteria, 60 (40%) had ILD.  On 
multivariate analysis the only three variables to remain significant were median 
duration of disease (OR 1.2 (1.1-1.3); p<0.001), speckled anti-nuclear antibody 
(ANA) pattern (OR 2.95 (1.22-7.15); p=0.017) and bibasal crackles (OR 5.4 (2.1-
13.5); p<0.0001).   
Univariate analysis of baseline variables associated with interstitial lung 
disease in systemic sclerosis. 
Baseline Variable ILD (n=60) Non-ILD (n=91) OR (CI 95%) p 
Bibasal crackles 
(%) 
28 (46.7) 10 (11.0) 7.1 (3.1-16.3) <0.0001 
Diffuse disease 
subtype (%) 
49 (81.7) 45 (48.9) 
 
4.6 (2.1-9.9) <0.001 
Limited disease 
subtype (%) 
8 (13.3) 
 
38 (41.3) 
 
0.2 (0.1-0.5) <0.001 
Anti-centromere 
antibodies (%) 
0 (0.0) 10 (13.0) - 0.006 
Cough (%) 21 (35.0) 15 (16.5) 2.7 (1.3-5.9) 0.007 
Median duration in 
years (IQR) 
6.1 (8.3) 4.0 (5.0) 2.2 (1.8-2.4) 0.009 
Speckled ANA 
pattern (%) 
29 (50.9) 25 (32.5) 2.5(1.2-4.9) 0.010 
Dyspnoea (%) 27 (45.0) 24 (26.4) 2.3 (1.1-4.6) 0.014 
Gold mining history 
(%) 
5 (8.3) 1 (1.1) 8.2 (0.9-71.9) 0.037 
ANA=antinuclear antibody; ILD=interstitial lung disease; IQR= interquartile range; OR=odds ratio 
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Additionally, dyspnoea was associated with ILD severity (p=0.008).  Bibasal crackles 
(p=0.014), increased plasma urea (p=0.041), and reduced serum albumin (p=0.007) 
were associated with mortality in the ILD group. 
CONCLUSION: Interstitial lung disease in South African SSc patients is common. 
The diffuse cutaneous disease subtype appears to drive the disease process.  There 
should be a high index of suspicion for ILD in SSc patients presenting with a gold 
mining history, dyspnoea, cough and bibasal crackles.  
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CHAPTER ONE:  INTRODUCTION AND LITERATURE REVIEW 
1.1 Overview of Systemic Sclerosis 
 
Systemic sclerosis (SSc) is a rare multi-system connective tissue disease.  It is 
characterised by progressive fibrosis of the skin and internal organs, vasculopathy, 
and disease-specific autoantibodies(1-3).  It is broadly divided into two types: limited 
cutaneous SSc (lcSSc), where the skin fibrosis is limited to the distal extremities and 
face; and diffuse cutaneous SSc (dcSSc), where the fibrosis extends proximal to the 
elbows and knees and additionally involves the trunk(4).  The pattern of organ 
involvement in SSc frequently involves skin and lung, but may include the 
gastrointestinal tract, musculoskeletal system, cardiovascular system, and renal 
system.  A more severe organ involvement is seen in those with dcSSc, compared to 
those with lcSSc.  In Caucasian dominant populations such as in Europe and North 
America lcSSc is more common (56%) than dcSSc (34%)(5), whereas in African-
American and Black populations the reverse is true, with rates of dcSSc of up to 82% 
being reported in Nigeria(6-9). 
 
Systemic sclerosis is also known as scleroderma (literally “thickened skin” from 
Greek derivation) and was first described in detail by the dermatologist Carlos Curzio 
in 1752, although scholars believe reference is made to this condition in the writings 
of Hippocrates(10).  The term scleroderma was coined by Giovambattista Fontanetti in 
1836(11), but it was not until 1945 that the systemic nature of the disease was 
highlighted by Robert Goetz, and the term systemic sclerosis (SSc) was more widely 
used(12).  The most “famous” of SSc patients was the Swiss artist Paul Klee (1879-
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1940) (pictured in Figure 1.1.1 with clear SSc facies), who was diagnosed after his 
death following a 5-year aggressive disease course(13).  His artwork is featured on 
the logo for the European League Against Rheumatism Scleroderma Trials and 
Research Group (EUSTAR).  His late work, shown in Figure 1.1.2, was created 
during his illness and clearly evokes the difficulties and suffering he experienced at 
the hands of SSc.  Understanding of SSc has progressed dramatically since Klee’s 
untimely demise, although many questions still remain. 
 
 
Figure 1.1.1 Artist Paul Klee, from a newspaper article in The Guardian (14) 
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Figure 1.1.2 “Angel applicant” by Paul Klee, 1939 (15) 
 
The underlying cause of SSc is thought to involve a complex interplay between an 
initiating environmental trigger, individual genetic predisposition, and immune 
dysfunction(1).  It has an estimated worldwide prevalence between 50 and 300 per 
one million population.  The incidence and prevalence varies geographically and 
amongst different ethnicities(1, 3, 16).  In a study carried out in South Africa at Chris 
Hani Baragwanath Academic Hospital (CHBAH) in Soweto, the average age of onset 
was 36 years(7), which is younger than described by other investigators where the 
peak age of onset was 45-55 years(17).  However, the ethnicity of the patients at 
CHBAH was exclusively Black, and world-wide African American patients with SSc 
are reported to present at a younger age and with more severe disease(2, 6, 18, 19).  
SSc is four times more common in women than in men(17, 19).   
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Studies on genetic susceptibility suggest that HLA/MHC-associated loci and other 
non-associated loci are involved in the pathogenesis of SSc(20).  The HLA-associated 
gene NOTCH4 has been linked to both SSc-specific antibodies: antitopoisomerase-I 
antibody (ATA) and anti-centromere antibody (ACA). The non-HLA associated gene 
IRF8 has been linked to lcSSc and ACA (21).  Choctaw Native Americans have a 
unique HLA haplotype which is thought to confer SSc susceptibility(16). These genetic 
associations may, with further elucidation, help to explain individual susceptibility to 
SSc, as well as help to explain the driving force behind associations between 
disease subtypes, laboratory features, and clinical outcomes, which are currently not 
clearly defined. 
 
Multiple environmental factors have also been implicated in SSc, including silica, 
bleomycin, and vinyl chloride.  In particular, silica exposure in gold-mining in men 
has been reported locally(22, 23), and internationally(24, 25) to increase the risk of 
developing SSc by a factor of between 3 and 28.  Although cigarette smoking has 
not been linked to the development of SSc, it has been linked to disease severity(26). 
 
Due to the association with autoantibodies, autoimmunity is thought to be involved in 
the pathogenesis of SSc.  Antinuclear antibodies (ANAs) are positive in 75-95% of 
SSc participants with a sensitivity of 85% and specificity of 54%(27).  There are two 
main patterns of staining in ANA: speckled and nucleolar.  Speckled patterns reflect 
ACA, and ATA, which are almost always mutually exclusive.  Additionally anti-U1-
ribonucleoprotein (RNP) and anti-RNA polymerase (RNAP)-II and -III give a 
speckled pattern. Nucleolar patterns of staining include anti-U3-RNP and RNAP-I.  
5 
 
The specific ANAs classically involved in SSc are ACA, ATA, and RNAP.  These 
autoantibodies vary with disease subtypes, outcomes, and the population involved, 
although there is overlap.  The ATA is very common (71%) in the Choctaw Native 
Americans(16), a population group with the highest rate of SSc worldwide.  American 
Caucasian SSc patients are reported to have an ATA positivity of 21%(6).  In a South 
African study from 1991, of the 73 ANA positive Black SSc patients in Durban, 32% 
were ATA positive(28).   Anti-topoisomerase I antibody itself seems to be associated 
with dcSSc (occurs in 40%) as well as interstitial lung disease (ILD) (occurs in 45%), 
and confers a more severe disease process(6).  Anti-centromere antibody is more 
common in Caucasian patients (25% versus 7% in African Americans)(6), and in 
those patients with lcSSc (40-60%)(6, 29, 30). 
 
As a multi-system disease the clinical presentation of SSc is variable.  Almost all 
patients have skin thickening (up to 5% have sine SSc).  In the initial stages of 
disease this may appear as a diffuse swelling of the hands and fingers, with 
arthralgia.  Progression to skin thickening occurs in differing distributions depending 
on dcSSc and lcSSc patterns. Joint deformities can occur through skin tightening or 
contractures.  Tendon friction rubs are more common in dcSSc and have been 
associated with organ involvement, particularly scleroderma renal crisis (SRC).  
Other skin manifestations include altered pigmentation (salt and pepper), calcinosis 
and telangiectasia(1-3).  Inflammatory arthritis may occur, as well as proximal 
weakness due to myositis. 
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Raynaud’s phenomenon is the commonest feature in terms of the vasculopathy 
(>95%)(1), which may be severe enough to result in tissue ischaemia.  This may be 
apparent on examination either as digital pulp loss, ischaemic pits, digital ulcers, or 
various capillary loop changes on nailfold capillaroscopy.  Other common 
vasculopathies are pulmonary arterial hypertension (PAH), although pulmonary 
hypertension may be secondary to SSc ILD, and SRC.  
 
Cardiac manifestations in SSc classically involve the myocardium with inflammation, 
ischaemia and fibrosis.   This may lead to systolic and diastolic dysfunction, as well 
as arrhythmias resulting from disruption of the conduction system.  Those with SSc 
are at higher risk of coronary vessel spasm. Pericardial disease also occurs 
including pericarditis, pericardial adhesions and pericardial effusions.  Asymptomatic 
pericardial effusions are the most common, especially when associated with 
pulmonary hypertension, although tamponade can occur.  Endocardial and valvular 
heart disease are rare(31).  In terms of indirect effects of SSc on the cardiac system, 
right heart failure may be secondary to ILD or PAH (1, 31). 
 
Gastrointestinal effects in SSc are common, where oesophageal dysmotility and 
dilatation may present with dysphagia or dyspepsia.  So-called “watermelon 
stomach” describes the endoscopic appearance of gastric antral vascular ectasia 
which usually causes anaemia.  Diarrhoea and bloating are also common complaints 
in SSc, due to bacterial overgrowth of the small intestine, and may be complicated 
by nutritional abnormalities (vitamin B12 and folate deficiencies)(1). 
7 
 
Scleroderma renal crisis is a life-threatening manifestation of SSc which presents as 
acute malignant hypertension (although up to 10% of patients are normotensive) in 
the presence of microangiopathic haemolytic anaemia and renal failure.  It is more 
common in those with tendon friction rubs, patients with rapidly progressive skin 
disease, those in the first 3 years of SSc diagnosis, those with anti-RNAP antibodies, 
and patients who have received high dose corticosteroids(1). 
 
Lung involvement in SSc is diverse and includes: aspiration pneumonia 
(oesophageal reflux and dysmotility), bronchiectasis, medication-induced 
pneumonitis, pneumonia, pleural effusion, extrinsic restriction from chest wall skin 
fibrosis, neuromuscular weakness, pulmonary vascular disease, lung malignancy, 
and ILD(1).  SSc ILD itself is a rather heterogenous umbrella term that involves 
inflammation and fibrosis of the lung parenchyma, including non-specific interstitial 
pneumonia (NSIP) as well as usual interstitial pneumonia (UIP).  NSIP occurs more 
frequently in SSc and is thought to represent an active inflammatory process, 
whereas UIP may be a “burnt out” fibrotic process(18, 32).  
 
SSc is associated with a substantially poorer survival compared to the general 
population.  As shown in Figure 1.1.3(33), leading causes of death have changed 
since the 1970s when SRC was by far the commonest.  The reduction in SRC has 
come about through its treatment with the advent of angiotensin converting enzyme 
inhibitors.  Among the leading causes of SSc related deaths currently are ILD and 
PAH; up to 42% of SSc patients with ILD die within 10 years of diagnosis(2, 33).  In 
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this context a better understanding of SSc ILD pathogenesis, natural history, 
progression, and an effective treatment are still sought.   
 
  
Figure 1.1.3.  Causes of death in SSc over a forty year period, Steen et al 
(2007)(33). SSc = systemic sclerosis; SRC=Scleroderma renal crisis; PAH = pulmonary arterial 
hypertension; GI = gastrointestinal; PF= pulmonary fibrosis. 
 
1.2 Overview of interstitial lung disease in systemic sclerosis 
 
The pathogenesis of SSc ILD has not yet been well elucidated, but the end-point is 
one of overproduction of extracellular matrix proteins by fibroblasts resulting in 
fibrosis, vasculopathy, and tissue ischaemia.  This is thought to be caused by 
abnormal and dysregulated interactions between endothelial cells, fibroblasts, and 
immune cells (Figure 1.2.1).  Endothelial cells secrete pro-inflammatory cytokines 
(Endothelin-1, Transforming Growth Factor Beta (TGF-β), and Platelet Derived 
Growth Factor (PDGF)), possibly in response to injury, which activate fibroblasts.  
The NOTCH4 gene identified by Gorlova et al (21) in SSc patients has been 
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implicated in this TGF-β pathway, which may contribute to the initiation of endothelial 
secretion.  Fibroblasts subsequently secrete interleukin-6 (IL-6) to activate T- and B-
lymphocytes.  T-lymphocytes promote a T-helper 2 response, predominantly through 
the secretion of interleukin-4 (IL-4), facilitating fibroblast proliferation and collagen 
synthesis.   B-lymphocytes are responsible for autoantibody production, the 
pathogenic role of which is uncertain.  There seems to be a reduced effectiveness in 
SSc patients of interferon-γ (IFN- γ) which normally acts as a potent suppressor of 
collagen synthesis by fibroblasts.  There also appears to be a role for reactive 
oxygen species (ROS), and resultant oxidative stress as either an initiating or 
exacerbating factor for endothelial cells, fibroblasts, and immune cells(18). 
 
Environmental factors associated with ILD include silica exposure in gold mining in 
men, which has been reported locally(22, 23), and internationally(2).  Cigarette smoking 
may be linked to ILD disease severity(2).   
 
The specific ANA most frequently associated with SSc ILD is ATA (45%)(29), whereas 
ACA may be protective as it is associated with non-ILD SSc manifestations(7, 18).  In a 
1999 South African study, Tager and Tikly(7) found a high cumulative occurrence of 
ATA (and lack of ACA) and ILD (56%) based on chest X-ray (CXR) findings in their 
exclusively Black participants, and that ILD was more common in those with dcSSc.   
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Figure 1.2.1 Pathophysiology of Systemic Sclerosis Interstitial Lung Disease 
(Bussonne et al (18)).  AECA=anti-endothelial cell antibodies; AFA=anti-fibroblast antibodies; 
CTGF=connective tissue growth factor; IFN-γ=interferon gamma; IL=interleukin; MCP-1=monocyte 
chemoattractant protein-1; PDGF=platelet-derived growth factor; RANTES=regulated on activation 
normal T-cell expressed and secreted; ROS=reactive oxygen species; TGF-β=transforming growth 
factor beta. 
 
Interstitial lung disease in SSc has a wide-ranging reported prevalence in the 
literature, from 16 to 91%(18, 34).  It is more common amongst male scleroderma 
patients, in contrast to the female predominance of SSc generally(1, 19, 35).  It occurs 
early in the SSc disease process: Solomon et al(32) reported that 25% of ILD patients 
were diagnosed with ILD within the first 3 years of SSc diagnosis; whereas Steen 
and Medsger(36) reported that 45-55% of severe ILD occurred in the first 3 years of 
SSc diagnosis.  In addition, McNearney et al.,(37) reported that African American 
patients have a higher rate of ILD (46%) compared to White (19%) and Hispanic 
(25%) patients, as well as a more severe ILD as measured by pulmonary function 
tests (PFTs).  Steen and colleagues(6) also reported a higher rate of ILD amongst 
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African American patients (52%) compared to White patients (11%), particularly 
those that were ATA positive (44% in African American SSc patients versus 18% 
Caucasian SSc patients).  Diffuse cutaneous disease is also more common in 
African American patients and is in itself more commonly associated with SSc ILD 
(although it does still occur in lcSSc).  Additionally, those with more extensive skin 
involvement are also more likely to develop ILD(38, 39).   
 
The apparent discordance of data in the literature may be because SSc is a rare 
disease and the numbers of patients recruited are often insufficient to apply broader 
conclusions.  Additionally, the methodology used to diagnose SSc ILD is not 
standardised.  Methods used include: CXR; high-resolution computer tomography 
(HRCT); PFT; lung biopsy; and broncho-alveolar lavage (BAL) washing analysis, and 
post-mortem histological analysis.  In the EUSTAR database of 7655 patients, the 
prevalence of ILD was found to be 32% by PFT, 40% by CXR and 52% by HRCT(40).  
Some have reported that clinical examination and CXR alone is robust enough to 
diagnose ILD in SSc patients(34), however to follow the progression of SSc ILD or to 
monitor response to treatment, PFT (particularly forced vital capacity (FVC)) and 
HRCT are recommended(34).  Measures of prognosticating SSc ILD include BAL 
analysis, although this is less popular currently due to its invasive nature(39). 
 
Patients with SSc ILD may complain of exertional dyspnoea, and a non-productive 
cough.  However, patients are often asymptomatic, particularly in the early stages of 
disease(1, 3), when they are most likely to develop SSc ILD.  On examination late 
inspiratory bibasal crackles may be found, although these can be difficult to 
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auscultate or absent in early disease.  Additionally, signs of pulmonary hypertension 
and cor pulmonale in late stages of the disease.  Routine investigations for ILD 
amongst newly diagnosed SSc patients have therefore been advocated(32, 41) which 
include CXR, PFT, and HRCT.  Chest X-ray may be normal in early disease, but 
may show a predominantly basal interstitial opacification in a reticulonodular pattern; 
PFTs may demonstrate a restrictive lung disease and decreased diffusion capacity 
for carbon monoxide (DLCO); and HRCT may reflect a wide variety of changes 
including ground-glass opacification, reticulonodular opacities, honeycombing, 
consolidation, or traction bronchiectasis.   
 
1.3 Interstitial lung disease treatment in systemic sclerosis 
 
Systemic sclerosis ILD is treated with immunosuppressive agents.  There is no 
“gold-standard” treatment protocol, and there are few double-blind randomized 
controlled studies in support of different agents.  Much of the rationale behind 
treatment comes from therapies used for idiopathic pulmonary fibrosis(18).  A difficulty 
in the literature around SSc ILD treatment lies in the differing measurements for 
efficacy and different end-points, rendering application of this data problematic. 
 
Hoyles et al., (2006)(42) required their study participants to have HRCT scans and 
lung biopsies prior to study recruitment, and measured improvement in FVC and 
DLCO to reflect improvement of ILD.  With their treatment of corticosteroids and 
intravenous cyclophosphamide, followed by maintenance oral azathioprine, there 
was a modest trend in improvement in lung function at 1 year.  Tashkin et al., 
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(2007)(43), as part of the Scleroderma Lung Study, recruited SSc participants with 
evidence of active ILD on HRCT, with or without BAL results.  They found the 
benefits of oral cyclophosphamide treatment (as measured by FVC, DLCO, skin 
scores, and dyspnoea indices) were temporary, so that the beneficial effects of the 
treatment regime disappeared within a year of stopping treatment. 
 
Some of the studies reviewed by Matucci-Cerinic et al., (2007)(44) and Nannini et al., 
(2008)(45), used stabilisation of FVC as an outcome measure rather than 
improvement of FVC, which appears to be achieved by both oral and intravenous 
cyclophosphamide regimes.  In a local study, Dheda et al., (2004)(46) also found 
some success with stabilisation of lung function and improvement of dyspnoeic 
symptoms using azathioprine and low-dose corticosteroids.  Additionally, there have 
been studies into the use of mycophenolate mofetil (MMF)(39), and rituximab(47), 
which seem to show similar results. 
 
The fact remains, however, that most studies fail to show long-lasting significant 
improvements in FVC with treatment.  Perhaps this is due to the failure to identify 
subsets of participants at risk of progression, as well as those most likely to respond 
to treatment.   
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1.4 Interstitial lung disease severity and progression in systemic 
sclerosis 
 
Patients who present with severe ILD (baseline FVC<50% predicted), and who have 
a progressive decline (of more than 10%) in FVC in the first year of symptom onset, 
appear to have a more aggressive course and higher mortality rate(18, 48-50).  African 
American patients have a more severe ILD (32% severe ILD in African American 
patients versus 13% severe ILD in Caucasian patients)(6) with a higher mortality rate 
compared to matched Caucasian patients(6, 32, 50).  In fact, the hazard ratio of 1.68 
(95% CI 1.30-2.16, p<0.0001) assigned to African American ethnicity was the most 
significant among all hazardous variables reported by Steen and Medsger(6). Others 
that were less significant include: age at first visit, male gender, and dcSSc. 
 
Goh et al (2008)(41), suggested an algorithm for grading of SSc ILD (Figure 1.4.1) 
whereby both HRCT and FVC severity are used to classify ILD into extensive and 
limited disease.  This was aimed at guiding clinicians on when to initiate treatment, 
and for which patients.  Those with extensive disease (>20% ILD on HRCT, and 
FVC<70%) should be treated, whilst those with limited ILD (<20% ILD on HRCT, and 
FVC≥70%) should be monitored.  Solomon and colleagues(32) then adapted this 
algorithm (Figure 1.4.2) to suggest a protocol for following up SSc ILD patients: 
those with limited ILD should monitored every 3-6 months for progression; and those 
without any evidence for ILD should be monitored with yearly PFTs. 
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Figure 1.4.1 Algorithm for the initiation of treatment of SSc ILD (Goh and 
colleagues, 2008(41)) 
 
 
Figure 1.4.2 Algorithm for follow up of SSc ILD patients (Solomon et al., 
2013(32)) 
 
Of interest in resource-poor settings, where HRCT (and possibly PFTs) may not be 
readily available, is the correlation between severity of lung fibrosis with clinical 
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parameters at presentation - namely skin scores, dyspnoea and cough.  Theodore et 
al., (2012)(51) found that cough correlated with severity of fibrosis, settled with 
treatment with cyclophosphamide, and returned with worsening disease activity.  
Assassi et al., (2010)(50), showed that in addition to a higher visual analogue score 
for dyspnoea, the presence of bibasal crackles on physical examination was 
associated with a poorer FVC at baseline.  Roth et al., (2011)(52) found that the 
Mahler baseline dyspnoea index, and the modified Rodnan skin score were 
predictive of response to cyclophosphamide.  Those with skin scores of more than 
23 and those with more than 50% involvement on HRCT showed a mean 
improvement in FVC of 9.81% at 18 months from baseline with treatment. 
 
Muangchan and colleagues (2012)(53) demonstrated that a baseline C-reactive 
protein (CRP) > 8 mg/litre was associated with “disease activity, severity, poor 
pulmonary function, and shorter survival.”  This was supported by Liu et al (2013)(54) 
who found that baseline CRP predicted progression in FVC decline, and is 
associated with shorter survival.   Other serological markers of interest are: KL-6 
(Krebs von den Lungen-6; a human mucin glycoprotein over-secreted by type II 
pneumocytes in SSc ILD patients); and SP-D (Surfactant protein D, also increased in 
SSc ILD patients compared to normal controls)(39).  However, neither KL-6 nor SP-D 
is available in the clinical setting as yet, whereas CRP is a widely used routine blood 
test in the setting of SSc. 
 
Whether those who attend the CHBAH Connective Tissues Diseases Clinic are 
comparable to SSc ILD patients described in the literature outlined above in terms of 
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disease spectrum and natural history, has yet to be established.  Particularly whether 
factors identified by other investigators could be applied to these patients in order to 
identify those at high risk of severe and progressive ILD to provide an early and 
effective intervention, is unknown.   
 
1.5 Aim 
 
To describe the profile of SSc ILD patients at the CHBAH Connective Tissue 
Diseases Clinic from 1 January 1992 until 31 May 2012, in order to better 
understand SSc ILD in South Africans. 
 
1.6 Objectives 
 
1. To determine the prevalence and spectrum of ILD in SSc patients and to 
describe the associations with baseline demographic, clinical and laboratory 
features. 
2. To determine the severity and progression of ILD in SSc patients and to 
describe associations with baseline demographic, clinical and laboratory 
features. 
3. To determine outcomes of treatment response for SSc ILD in terms of any 
significant changes from baseline FVC, and to determine baseline factors that 
could predict response. 
4. To determine survival among SSc ILD participants, and to identify any 
baseline variables that are associated with mortality.  
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CHAPTER TWO:  PATIENTS AND METHODS 
 
2.1  Study design 
 
A single-centre retrospective observational study of adult patients with SSc ILD at 
the Connective Tissue Diseases Clinic at CHBAH.  Inclusion criteria included: age  
18 years; all patients with SSc registered at the Connective Tissue Diseases Clinic, 
CHBAH, from 1 January 1992 until 31 May 2012; all patients met the American 
College of Rheumatology preliminary classification criteria for SSc (55) (Appendix A); 
adequate records with respect to HRCT and PFT.  The only exclusion criterion was 
inadequate records. Ethical approval was granted from the Human Research Ethics 
Committee (Medical) at the University of Witwatersrand (Appendix C).   
 
2.2  Data collection 
 
Data was retrieved from clinic files from patients presenting from 1 January 1992 
until 31 May 2012.  A data collection sheet was used (Appendix B) to record 
demographical, clinical assessments, laboratory data, and investigations at initial 
presentation.  Additionally, treatment received over the course of the disease 
duration was noted, as well as overall survival.  In terms of survival, it was recorded 
whether patients were known deceased, alive, or had been lost to follow up.  Cause 
of death was documented as infection, malignancy, ILD, cardiovascular, or unknown.  
Cardiovascular causes of death included myocardial infarction, cardiomyopathy, and 
heart failure, or complications thereof.  Age at SSc diagnosis was defined as the age 
in years at diagnosis of SSc by a rheumatologist. Duration of disease was defined as 
time in years from diagnosis until either last clinic appointment, or date of confirmed 
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death.  Smoking history was judged to be positive if the participant had smoked at 
any stage (either previously or currently).  Digital lesions (digital ulcers, scars, or 
gangrene) were grouped together as indicative of cutaneous vasculopathy.  Nailfold 
changes were documented as dilated capillary loops, haemorrhages, or capillary 
drop out.  Disease classifications were either diffuse cutaneous, limited cutaneous, 
based on descriptions by LeRoy and colleagues(4).  Unclassified SSc was allocated 
to those participants where there was insufficient data for classification (early SSc or 
sine SSc), or where an overlap syndrome existed (SSc overlapping with rheumatoid 
arthritis, for example).  
 
SSc ILD was defined based on features of ILD on HRCT (groundglass opacification, 
fibrosis, and honeycombing) as judged by a pulmonologist or radiologist, with or 
without restrictive PFTs.  High resolution computed tomography was ordered for all 
patients where ILD was suspected on clinical grounds (symptoms, bibasal crackles 
on examination, suggestive CXR or PFTs).  The ILD diagnosis was recorded as a 
cumulative event.  Pulmonary function tests were defined as restrictive if FEV1:FVC 
> 80% and impaired if FVC < 70% that of predicted, in line with Goh et al (2008) (41).  
Impairment of FVC was classified as mild if FVC≥70%, moderate if FVC 50-69%, 
and severe if FVC<50%.  Pulmonary function tests were collected at baseline (at the 
time of ILD diagnosis), and at 6 months, 1 year, and 2 years from baseline.  
Treatment response was classified as: 
 Improved if FVC increased by  10% from baseline 
 Stable if FVC remained within 10% of baseline 
 Worsened if FVC declined by  10% from baseline 
20 
 
As such, participants who stabilised or improved were classified as having non-
progressive ILD, and those who worsened were classified as having progressive 
ILD. 
 
2.3  Data analysis and statistical methods 
 
All the data collected using the data sheet (Appendix B) was entered into a database 
using Microsoft Excel.  Appropriate descriptive analyses were performed on the 
demographic, clinical, and laboratory characteristics of all patients with SSc.  
Continuous data was tested for normality, and when found not to be normally-
distributed, was converted using a logarithmic scale.  Continuous data was 
expressed as means (± standard deviation (SD)) or medians (interquartile range 
(IQR)), the latter being used when the SD was greater than the mean.  Categorical 
data was expressed as percentages. 
 
Comparisons were made between participant groups using the 2-tailed Fisher’s 
exact test for frequency data as n was often less than 5.  For any frequency data 
larger than a 2x2 contingency table one-way ANOVA was used.  The 2-tailed 
unpaired Student’s t-test was used for quantitative data comparisons.  A p<0.05 was 
considered statistically significant.  The computation of odds ratios was done using a 
binary logistical option at a 95% confidence interval for all odds ratios.  Multivariate 
logistical regression analysis was applied using the ENTER method(56) with all 
variables pre-determined from significance.  The entry point was at p=0.05 and the 
exit point was at p=0.10.  
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CHAPTER THREE:  RESULTS 
 
3.1  Characteristics of overall systemic sclerosis cohort 
 
A total of 177 patient files were examined, 151 of whom met the inclusion criteria.  
As such, 26 participants were excluded due to incomplete records or a diagnosis 
other than that of SSc (systemic lupus erythematosis, morphea, eosinophilic 
fasciitis).  The overall findings for all participants at presentation are shown in Table 
3.1.1.   The majority of SSc participants were female (87.4%), and of Black ethnicity 
(86.2%).  The remaining 13.8% of the patients were made up of Caucasian (2.7%), 
mixed race (0.7%), and Indian (3.3%) ethnicities.  In 6.6% of patients ethnicity was 
not specified.  The mean age (SD) at diagnosis was 44.1 years (13.0).  The most 
common clinical findings were Raynaud’s phenomenon (82.8%) and nailfold 
changes (70.2%), with the most common disease subtype being diffuse cutaneous 
(62.2%). 
 
The average values (either mean or median, as appropriate) for blood tests in terms 
of urea (Ur), creatinine (Cr), white cell count (WCC), haemoglobin (Hb), mean cell 
volume (MCV), platelets, albumin (Alb), were all within normal ranges.  Seventeen 
participants (11.3%) had renal impairment with Cr>100mmol/l at presentation, 49 
(32.5%) were anaemic with Hb<12g/dl, 8 (5.3%) had leukopaenia (WCC<4.0x109/l), 
4 (2.6%) had thrombocytopaenia (<100 x 109/l), 65 (49.6%) had hypoalbuminaemia 
of less than 40g/l, and roughly half of the participants had raised inflammatory 
markers (CRP and ESR, erythrocyte sedimentation rate). Nine participants (6.0%) 
were HIV positive.  There was insufficient data to allow meaningful description or 
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analysis for vital signs, height, weight, Rodnan skin scores, urine analysis, 
echocardiogram, chest X-ray, barium swallow or gastroscopy. 
 
Table 3.1.1 Overall baseline features of all systemic sclerosis participants 
Demographics n=151 (%)* 
Female:Male 
Mean age at diagnosis in years (SD) 
Median duration in years (IQR) 
Black ethnicity 
7:1 
44.1 (13.0) 
4.0  (6.0) 
131 (86.2) 
History  
Gold-mining history  
Smoking history (n=130) 
Raynaud’s phenomenon  
Reflux  
Proximal weakness  
Arthralgia  
Dyspnoea  
Cough  
6 (4.0) 
20 (15.4) 
125 (82.8) 
85 (56.3) 
  56 (37.1) 
 90 (59.6) 
 52 (34.4) 
37 (24.5) 
Examination  
Digital lesions  
Nailfold changes  
Telangiectasia  
Calcinosis  
Arthritis  
Tendon friction rubs  
Proximal Myopathy  
Scleroderma renal crisis  
Bibasal crackles   
66 (43.7) 
106 (70.2) 
19 (12.6) 
13 (8.6) 
33 (21.9) 
15 (9.9) 
56 (37.1) 
3 (2.0) 
39 (25.8) 
Disease subtype  
Diffuse cutaneous systemic sclerosis  
Limited cutaneous systemic sclerosis  
Unclassified systemic sclerosis 
94 (62.2) 
46 (30.5) 
11 (7.3)  
Laboratory Features  
Renal dysfunction (Cr>100mmol/l)   
Leukopaenia (WCC<4.0x109/l)  
Anaemia (Hb<12.0g/dl)  
Thrombocytopaenia (<100 x 109/l)  
Hypoalbuminaemia (<40 g/l)  (n=131) 
HIV positive  
CRP > 8mg/l  
ESR >20 mm/hr  
17 (11.3) 
8 (5.3) 
49 (32.5) 
4 (2.6) 
65 (49.6) 
9 (6.0) 
61 (40.4) 
83 (55.0) 
HIV=human immunodeficiency virus; CRP=C-reactive protein; ESR=erythrocyte sedimentation rate; 
Cr=creatinine; Hb=haemoglobin; WCC=white cell count; * (%) unless otherwise stated. 
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As demonstrated in Table 3.1.2, the majority of participants were ANA positive 
(88.1%).  Of those who were ANA positive, the most common ANA patterns were 
speckled (40.6%) and nucleolar (31.6%).  Anti-topoisomerase I antibody was present 
in 18.8% of participants while only 7.5% of participants had a positive ACA.  
Interestingly, 24.4% of those who had dcSSc were ATA positive whereas only 5.4% 
of lcSSc participants were ATA positive (p=0.021).  In contrast, 21.6% of those who 
had lcSSc were ACA positive whereas only 1.1% of those who had dcSSc were ACA 
positive (p<0.001). 
 
Table 3.1.2.  Autoantibody profiles in overall group and systemic sclerosis 
subtypes   
Anti-nuclear antibodies  Overall 
(n=151) 
Diffuse 
cutaneous 
(n=94) 
Limited 
cutaneous 
(n=46) 
p 
Positive ANA (%) 
Speckled ANA pattern (%) 
Homogenous ANA pattern (%) 
Nucleolar ANA pattern (%) 
Anti-centromere antibody (%) 
Anti-topoisomerase I antibody (%) 
133 (88.1) 
54 (40.6) 
4 (3.0) 
42 (31.6) 
10 (7.5) 
25 (18.8) 
87 (91.5) 
33 (38.4) 
2 (2.3) 
30 (34.9) 
1 (1.1) 
21 (24.4) 
37 (80.4) 
17 (45.9) 
1 (2.7) 
9 (24.3) 
8 (21.6) 
2 (5.4) 
ns 
ns 
ns 
ns 
<0.001 
0.021 
ANA=antinuclear antibodies; ns=not significant. 
 
In terms of survival, approximately 40% of patients were lost to follow up, 45% were 
known to be alive, and 14.6% were confirmed to have died (see Table 3.1.3).  The 
cause of death was known in 16 of the 22 participants who had died (72.7%). 
Infection (27.3%) was the commonest cause of death, followed by ILD (18.2%), 
cardiovascular (18.2%), and malignancy (9.1%). 
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Table 3.1.3 Overall survival of all systemic sclerosis participants   
Outcome n (%) 
Lost to follow up  
Alive  
Demised  
61 (40.4) 
68 (45.0) 
22 (14.6) 
Cause of death (n=22): Infection  
Unknown  
ILD  
Cardiovascular  
Malignancy  
6 (27.3) 
6 (27.3) 
4 (18.2) 
4 (18.2) 
2 (9.1)  
ILD=interstitial lung disease 
 
3.2  Associations of interstitial lung disease with demographic, 
clinical and laboratory features 
 
Of the 151 participants evaluated, 60 (39.7%) were diagnosed with ILD based on 
HRCT findings, with or without PFTs.  A total of 56 ILD patients had HRCTs, 52 of 
whom had available reports.  In the available HRCT reports, 26 participants (50.0%) 
had ground glass, 31 (59.6%) had honeycombing, and 12 (23.1%) had fibrosis, with 
22 (42.3%) having a combination of these.  There was only one patient (1.7%) who 
was unable to perform PFTs due to ill health, although due to lack of availability at 
the time 7 patients (11.7%) did not have full lung function at diagnosis, and 29 
(49.2%) did not have full lung function at follow up.  No participants had lung 
biopsies performed.   
 
In the ILD group there was a longer median disease duration (6.2 years versus 4.0 
years; p=0.009) (Table 3.2.1).  The majority of ILD patients (63.3%) were diagnosed 
with ILD the same year as their SSc diagnosis, and 73.3% within 3 years of their SSc 
diagnosis. 
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Table 3.2.1 Baseline features in ILD and non-ILD participants  
Demographics ILD (n=60) (%)* Non ILD (n=91) (%)* p 
Female:Male 
Mean age at diagnosis in years (SD) 
Median duration in years (IQR) 
Black ethnicity  
5:1 
42.7 (12.1) 
6.1  (8.3) 
53  (88.3) 
9:1 
45.0  (13.4) 
4.0  (5.0) 
78  (85.7) 
ns 
ns 
0.009 
ns 
History    
Gold mining history  
Smoking history  
Raynaud’s phenomenon  
Reflux  
Proximal weakness  
Arthralgia  
Dyspnoea  
Cough  
5 (8.3) 
8 (15.7) (n=51) 
50  (83.3) 
33  (55.0) 
24  (40.0) 
37  (61.7) 
27  (45.0) 
21  (35.0) 
1 (1.1) 
11 (13.8) (n=80) 
74  (81.3) 
51  (56.0) 
32  (35.2) 
52  (57.1) 
24  (26.4) 
15  (16.5) 
0.037 
ns 
ns 
ns 
ns 
ns 
0.014 
0.007 
Examination    
Digital lesions  
Nailfold changes  
Telangiectasia  
Calcinosis  
Arthritis  
Tendon friction rubs  
Proximal Myopathy  
Scleroderma renal crisis  
Bibasal crackles  
24 (40.0) 
39 (65.0) 
6 (10.0) 
7 (11.7) 
14 (23.3) 
4 (6.7) 
19 (31.7) 
1 (1.7) 
28 (46.7) 
42 (46.2) 
66 (72.5) 
13 (14.3) 
5 (5.5) 
19 (20.9) 
11 (12.1) 
36 (39.6) 
2 (2.2) 
10 (11.0) 
ns 
ns 
ns 
ns 
ns 
ns 
ns 
ns 
<0.0001 
Disease subtype    
Diffuse cutaneous systemic sclerosis 
Limited cutaneous systemic sclerosis 
Unclassified systemic sclerosis 
49 (81.7)  
8 (13.3) 
3 (5.0) 
45 (48.9) 
38 (41.3) 
8 (8.7) 
<0.001 
<0.001 
ns 
Laboratory Features    
Renal dysfunction (Cr >100 mmol/l)  
Leukopaenia (<4.0 x 109/l)  
Anaemia (Hb<12.0g/dl)  
Thrombocytopaenia (<100 x 109/l)  
Hypoalbuminaemia (<40 g/l)   
HIV positive  
CRP > 8mg/l  
ESR >20 mm/hr 
4 (6.7) 
2 (3.3) 
20 (33.3) 
4 (6.7) 
29 (48.3) (n=55) 
4 (6.8) 
26 (49.1) (n=53) 
34 (57.6) (n=59) 
13 (14.3) 
6 (6.6) 
29 (31.9) 
0 (0.0) 
36 (23.8) (n=76) 
5 (5.5) 
35 (44.3) (n=79) 
47 (54.7) (n=86) 
ns 
ns 
ns 
0.023 
ns 
ns 
ns 
ns 
Autoantibodies    
Positive ANA 
Speckled ANA pattern 
Homogenous ANA pattern 
Nucleolar ANA pattern  
Anti-centromere antibody 
Anti-topoisomerase I antibody  
57 (95.0) 
29 (50.9) 
3 (5.3) 
13 (22.8) 
0 (0.0) 
13 (22.8) 
76 (83.5) 
25 (32.9) 
1 (1.3) 
29  (38.2) 
10  (13.2) 
12  (15.8) 
0.065 
0.010 
ns 
ns 
0.006 
ns 
ILD=interstitial lung disease; IQR=interquartile range; SD=standard deviation; ns=non-significant; 
HIV=human immunodeficiency virus; CRP=C-reactive protein; ESR=erythrocyte sedimentation rate; 
ANA=anti-nuclear antibodies; * = (%) unless otherwise stated. 
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Figure 3.2.1 History findings of ILD and non-ILD participants.  ILD = interstitial lung 
disease 
 
 
Figure 3.2.2 Examination findings of ILD and non-ILD participants. ILD= interstitial 
lung disease; SRC=scleroderma renal crisis. 
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Figure 3.2.3 Disease subtype in ILD and non-ILD participants.  ILD = interstitial lung 
disease. 
 
In terms of participant history at presentation, the only significant associations at 
presentation with SSc ILD were Gold-mining history (p=0.037), dyspnoea (p=0.014), 
and cough (p=0.007), as shown in Figure 3.2.1.  The only examination finding at 
presentation that showed a significant association with ILD was bibasal crackles 
(p<0.0001), as demonstrated in Figure 3.2.2.  The dcSSc disease subtype was 
associated with the ILD group (81.7% versus 48.9% in non-ILD patients; p<0.001), 
whereas the lcSSc was associated with the non-ILD group (41.3% versus 13.3% in 
the ILD group; p<0.001).    
 
In terms of laboratory results there were no significant differences between the 
average (either mean or median, as appropriate) values for ILD and non-ILD groups 
for full blood counts, urea and creatinine, inflammatory markers, albumin, and HIV 
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status.   All the participants with thrombocytopaenia were in the ILD group (6.7% 
versus 0%; p=0.023).  The clinical significance of this is unclear as none of these 
participants were HIV positive or had overlap disease. 
 
On anti-nuclear antibody results, a positive ANA trended toward significance in the 
ILD versus non-ILD group (95.0% vs 83.5% respectively; p=0.065).  The ANA 
pattern and specific autoantibodies did show significant differences between the ILD 
and non-ILD groups, as illustrated in Table 3.2.1 and Figure 3.2.4.  The speckled 
ANA pattern was commoner in the ILD group (50.9% versus 32.9% in non-ILD 
group; p=0.010). In contrast, ACA was less common in the ILD group (0% versus 
13.2% in the non-ILD group, p=0.006).  In other auto-antibody testing (anti double-
stranded DNA, anti-Ro, anti-La, anti-Smith, and anti-RNP), there were no significant 
differences between ILD and non-ILD groups. 
 
In the multivariate logistic regression analysis significant variables associated with 
ILD were entered simultaneously; p for entry 0.05, p for removal 0.10.  The odds 
ratios with confidence intervals (CI) set at 95% are demonstrated in Table 3.2.2 and 
represent an r2 of 0.499 (Negelkerke).   The 95% CI for Gold-mining history, 
dyspnoea, cough, and disease subtype all spanned unity, whereas disease duration, 
bibasal crackles, and speckled ANA all showed a predictive relationship to SSc ILD.  
Due to the fact that ACA had a zero frequency in the ILD group, odds ratios could 
not be calculated, although a protective relationship was suggested in univariate 
analysis. 
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Figure 3.2.4 Autoantibodies in ILD and non-ILD participants.  ILD = interstitial lung 
disease; ACA=anti-centromere antibody; ATA=anti-topoisomerase. 
 
Table 3.2.2. Multivariate analysis for baseline predictors of ILD in systemic 
sclerosis   
Variable Odds ratio (95% confidence intervals) p 
Bibasal crackles  9.43 (3.25-27.39) <0.0001 
Disease duration 1.19 (1.09-1.30) <0.0001 
Speckled ANA 2.95 (1.22-7.15) 0.017 
Gold mining  5.90 (0.49-70.78) ns 
Dyspnoea  1.05 (0.38-2.86) ns 
Cough  2.60 (0.86-7.87) ns 
Diffuse cutaneous disease  4.36 (0.79-24.23) ns 
Limited cutaneous disease  0.86 (0.14-5.26) ns 
ANA= anti-nuclear antibody.        r
2
 = 0.499 
 
3.3  Interstitial lung disease severity in systemic sclerosis 
 
Of the 60 ILD SSc participants, 59 were able to perform PFTs.  The mean FVC % 
predicted (SD) at SSc ILD diagnosis was 78.4 (22.1).  Participants were categorised 
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into mild ILD (FVC≥70%), moderate ILD (FVC 50-69%), and severe ILD (FVC<50%) 
at point of SSc ILD diagnosis. The mean FVC % predicted (SD) for each category 
were 98.0 (17.5), 66.2 (8.0), 38.0 (12.1) respectively.   As there were only 3 
participants with FVC<50%, moderate and severe ILD were grouped together.  Thus 
the ILD group was subdivided into FVC≥70% (n=36; mean FVC 92.1%; SD 18.1) 
and FVC<70% (n=23; mean FVC 58.8%; SD 10.6).  A comparative analysis was 
performed between these two severity subgroups to establish if there were any 
statistically significant associations with baseline variables.   
 
The number of patients in the mild ILD group that were diagnosed in the same year 
as their SSc diagnosis was 19 (52.8%), whereas 17 (73.9%) of the moderate-severe 
ILD group were diagnosed in the same year of SSc diagnosis (p=0.013).  The only 
variables at baseline that either trended toward significance or were significantly 
associated with ILD severity were amongst the history findings: those participants in 
the more severe ILD group had a higher percentage of participants with a history of 
gold mining (17.4 % vs 2.8% of participants in FVC≥70%), which trended towards 
significance (p=0.066); and those participants with more severe ILD were 
significantly associated with a history of dyspnoea at baseline (p=0.008).  
 
3.4  Interstitial lung disease progression in systemic sclerosis 
 
Of the 59 SSc ILD participants able to perform PFTs, 39 had follow-up PFTs at 6 
months from ILD diagnosis.  There was insufficient data for analysis at 1 year and 2 
year follow-up PFTs.  The 6-month follow-up PFT results were classified into those 
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that demonstrated a decline in FVC of greater than 10% (progressive ILD; n=9 
(23.1%)), and those that demonstrated either an improvement or stabilisation in FVC 
within 10% of baseline (non-progressive ILD; n=30 (76.9%)).  The mean baseline 
FVC % predicted (SD) for the non-progressive ILD group was 76.7 (24.8), and for 
the progressive ILD group was 80.8 (20.2).  The mean FVC % predicted (SD) at 6 
month follow-up in the progressive ILD group was 63.4 (16.8), with a mean decline in 
FVC % predicted (SD) of 21.2 (8.4) from baseline.  There was no significant 
difference between progressive and non-progressive ILD groups in terms of time 
from SSc diagnosis to ILD diagnosis.  A comparative analysis was performed 
between ILD progressive and ILD non-progressive participants to establish if there 
were any statistically significant associations between baseline variables and ILD 
progression at 6 months.  There were no significant associations found. 
 
3.5  Interstitial lung disease treatment in systemic sclerosis 
 
The median time (IQR) taken from SSc diagnosis until SSc ILD diagnosis was 0 
years (1).  The median time (IQR) from SSc ILD diagnosis until SSc ILD treatment 
was 1 month (3).  Of note is that 10 of the 60 SSc ILD participants were started on 
immunosuppression for other complications of SSc (severe skin disease, myositis, 
and others) prior to SSc ILD diagnosis.  The data for both ILD subgroups, based on 
severity and progression, is displayed in Table 3.5.1.   
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Table 3.5.1 Time from systemic sclerosis diagnosis to interstitial lung disease 
diagnosis and treatment 
 FVC≥70% 
(n=36) 
FVC<70% 
(n=23) 
p Non-
progressive 
ILD (n=30) 
Progressive 
ILD 
(n=9) 
p 
Time from SSc 
diagnosis to SSc 
ILD diagnosis in 
years (IQR) 
0 (1) 0 (0.5) ns 0 (1) 0 (2) ns 
Time from SSc ILD 
diagnosis to SSc 
ILD treatment in 
months (IQR) 
1 (4) 1 (2) ns 1 (3) 4 (4) ns 
SSc=systemic sclerosis; FVC=forced vital capacity; ILD= interstitial lung disease. 
 
As evidenced by the IQR values in table 3.5.1, there was a single participant in 
whom there was a delay of 85 months between ILD diagnosis and initiation of ILD 
treatment.  This was because at ILD diagnosis the participant was asymptomatic and 
had UIP changes on HRCT, and therefore no treatment was given.  Eighty-five 
months later this participant developed dyspnoea and NSIP changes on HRCT and 
was thus initiated on ILD treatment.  Overall, there were no significant differences 
between the severity or progression ILD subgroups in terms of time to ILD diagnosis 
or time to ILD treatment. 
 
The types of treatment administered to the ILD participants are shown in Table 3.5.2.  
Of the 60 SSc ILD participants, only 9 received no treatment for ILD (15.0%), the 
majority of whom were in the mild ILD and non-progressive ILD subgroups.  Prior to 
the introduction of cyclophosphamide, D-penicillamine was used in the treatment of 
SSc ILD.  Corticosteroids were used in conjunction with cyclophosphamide as an 
induction therapy followed by maintenance with either azathioprine or MMF.  The 
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only significant difference between the two ILD subgroups in terms of treatment was 
that a higher percentage of patients in the non-progressive ILD subgroup received D-
penicillamine (16.7% vs 11.1% in the progressive ILD subgroup, p=0.043).     
 
Of the 51 SSc ILD participants who received treatment, only 7 (13.7%) developed 
complications during this treatment: 4 (7.8%) developed pulmonary tuberculosis; 2 
(3.9%) developed haemorrhagic cystitis from cyclophosphamide; and 1 developed 
pneumonia (other than tuberculosis).  There were no significant associations 
between ILD subgroups in this regard, as shown in Table 3.5.3. 
 
Table 3.5.2 Interstitial lung disease treatments for subgroups 
Treatment FVC≥70
% 
(n=36) 
FVC<70
% 
(n=23) 
p Non-
progressive 
ILD (n=30) 
Progressive 
ILD 
(n=9) 
p 
Intravenous 
Cyclophosphamide  (%) 
20 (55.6) 15 (65.2) ns 21 (70.0) 5 (55.6) ns 
D-Penicillamine (%) 6 (16.7) 4 (17.4) ns 5 (16.7) 1 (11.1) 0.043 
Azathioprine (%) 11 (30.6) 5 (21.7) ns 10 (33.3) 3 (33.3) ns 
MMF (%) 6 (16.7) 3 (13.0) ns 3 (10.0) 4 (44.4) ns 
Methotrexate (%) 4 (11.1) 6 (26.1) ns 3 (10.0) 1 (11.1) ns 
Corticosteroids 
(>10mg/day) (%) 
26 (72.2) 18 (78.3) ns 25 (83.3) 5 (55.6) ns 
No treatment (%) 6 (16.7) 2 (8.7) ns 4 (13.3) 2 (6.7) ns 
FVC=forced vital capacity; ILD=interstitial lung disease; MMF= Mycophenalate mofetil. 
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Table 3.5.3.  Complications during interstitial lung disease treatment   
Complications FVC≥70% 
(n=36) 
FVC<70% 
(n=23) 
p Non-
progressive 
ILD (n=30) 
Progressive 
ILD 
(n=9) 
p 
Tuberculosis (%) 2 (5.5) 2 (8.7) ns 2 (6.7) 1 (11.1) ns 
Other (%) 1 (2.8) 2 (8.7) ns 2 (6.7) 0 (0.0) ns 
FVC=forced vital capacity; ILD=interstitial lung disease. 
 
3.6  Interstitial lung disease survival in systemic sclerosis 
 
The outcome of participants was recorded as: lost to follow up, alive, or deceased.  
Of the participants that were deceased, cause of death (if known) was recorded.  
There was insufficient data in this regard for any meaningful analysis.  The results of 
ILD versus non-ILD participant outcomes are displayed in Table 3.6.1 and the ILD 
subgroup outcomes are displayed in Table 3.6.2.  Approximately 40% of all 
participants were lost to follow up, and approximately 15% demised.  
 
Table 3.6.1 Survival of ILD and non-ILD systemic sclerosis participants   
Survival ILD (n=60) Non-ILD (n=91) p 
Lost to follow up (%) 25 (41.7) 36 (39.6) ns 
Alive (%) 26 (43.3) 42 (46.2) ns 
Deceased (%) 9 (15.0) 13 (14.3) ns 
ILD=interstitial lung disease. 
 
The percentage of participants who died in the moderate-severe ILD group 
compared to the mild ILD group were similar (13.0% versus 16.7%; p=ns).  However, 
the percentage of participants who died in the progressive ILD group was greater 
compared to the non-progressive ILD group (33.3% versus 10.0%; p=ns). 
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Table 3.6.2 Survival of ILD subgroup participants  
Survival FVC≥70% 
(n=36) 
FVC<70% 
(n=23) 
p Non-
progressive 
ILD  (n=30) 
Progressive 
ILD 
(n=9) 
p 
Lost to follow up 
(%) 
14 (38.9) 10 (43.5) ns 10 (33.3) 3 (33.3) ns 
Alive (%) 16 (44.4) 10 (43.5) ns 17 (56.7) 3 (33.3) ns 
Deceased (%) 6 (16.7) 3 (13.0) ns 3 (10.0) 3 (33.3) ns 
FVC= forced vital capacity; ILD=interstitial lung disease. 
 
Of the 9 (15.0% of all ILD participants) ILD participants who were known to have 
demised, 4 (44.4%) died from ILD, 2 (22.2%) died from infections, and in a third of 
patients the cause of death was unknown.  This contrasted to the non-ILD group 
where infection and cardiovascular were the joint leading causes of death (30.8%), 
followed by malignancy (15.4%).  In the non-ILD group, 3 participants (23.1%) who 
died had no clear cause of death.  These results are summarised in Table 3.6.3. 
 
Table 3.6.3 Causes of death of ILD and non-ILD systemic sclerosis participants  
Cause of death ILD (n=9) Non-ILD (n=13) p 
Infection (%) 2 (22.2) 4 (30.8) ns 
Malignancy (%) 0 (0.0) 2 (15.4) ns 
Cardiovascular (%) 0 (0.0) 4 (30.8) ns 
ILD (%) 4 (44.4) 0 (0.0) 0.017 
Unknown (%) 3 (33.3) 3 (23.1) ns 
ILD=interstitial lung disease. 
 
In order to identify any significant associations in the ILD group with those who had 
deceased, baseline variables were compared in ILD participants who were alive 
(n=26), and those ILD participants who were deceased (n=9). Those who were lost 
to follow up were excluded as their status in this respect was unknown.  The 
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baseline variables that either trended toward significance or were statistically 
significant are shown in Table 3.6.4.   
 
Table 3.6.4 Significant associations between presentation variables and ILD 
survival   
Variable at presentation ILD alive (n=26) ILD deceased 
(n=9) 
p 
Median duration in years (IQR) 7.0 (10.0) 2.0 (6.0) <0.0001 
Proximal weakness (%) 9 (34.6) 2 (22.2) 0.035 
Telangiectasia (%) 4 (15.4) 0 (0.0) 0.028 
Bibasal crackles (%)  10 (38.5) 6 (66.7) 0.014 
Diffuse disease subtype (%)  21 (80.8) 8 (88.9) 0.073 
Mean Urea mmol/l (SD) 3.4 (1.6) Median = 4.7 
(IQR: 1.9) 
0.041 
Average Creatinine mmol/l  Mean = 60.4 
(SD=15.5) 
Median = 67.0 
(IQR=19.0) 
0.086 
Mean Albumin g/l (SD) 39.1 (3.5) (n=23) 34.0 (6.9) 0.007 
Median CRP in mg/l (IQR) 6.0 (8.2) 
(n=21) 
9.2 (40.8) 0.066 
CRP > 8mg/l (%) 7 (33.3) (n=21) 6 (66.7) 0.065 
ILD=interstitial lung disease; CRP= C-reactive protein. 
 
As demonstrated in Table 3.6.4, the median duration in years of SSc was 
significantly longer in ILD alive participants compared to  ILD deceased participants 
(7.0 versus 2.0, respectively; p<0.0001).  Proximal weakness was more often 
reported in alive ILD patients compared to those that died (34.6% versus 22.2%, 
p=0.035), as well as telangiectasia (15.4% versus 0%, p=0.028).  Bibasal crackles at 
presentation was more common in ILD participants that died (66.7% versus 38.5%; 
p=0.014).  Diffuse cutaneous SSc was more common amongst ILD participants who 
died (88.9% versus 80.8%, p=0.073), which trended toward significance.   
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In terms of blood test results, the average plasma urea was higher in the deceased 
ILD group (10.8 mmol/l versus 3.4 mmol/l in the alive ILD group, p=0.041), as was 
the average creatinine (157.8 mmol/l versus 60.4 mmol/l in the alive ILD group, 
p=0.086).  This result may be affected by a single participant in the ILD deceased 
group that had SRC, as the median values between the two groups are comparable.  
The mean serum albumin was significantly lower in the ILD deceased subgroup 
compared to the ILD alive group (34.0 g/l versus 39.1 g/l; p=0.007).  The median 
CRP was higher in the deceased group (9.2 mg/l versus 6.0 mg/l; p=0.066), and a 
higher proportion of participants in the deceased group had a CRP>8 mg/l (66.7% 
versus 33.3%; p=0.065), which trended towards significance. 
 
On performing odds ratios on the above baseline variables with 95% confidence 
intervals using the ENTER method, all variables straddled unity and were thus not 
significant.  
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CHAPTER FOUR:  DISCUSSION 
 
4.1  Characteristics of overall systemic sclerosis cohort 
 
There were 151 SSc participants in this study.  The majority were female (7:1), and 
of Black ethnicity (>85%).  The female predominance was more marked than 
previously reported both locally and internationally where a ratio of 4:1 was found.  
There may be an under-representation of male SSc patients in this study, but it is not 
clear why this would be.   Numerically, the mean age at diagnosis was similar to the 
average age of onset in other studies which reported this to be 45-55 years(17).  
However, these two concepts are not synonymous, making comparison difficult.  Age 
of onset is prone to error in terms of recall bias, and onset of symptoms (Raynaud’s 
or non-Raynaud’s) are variably reported in the literature, hence the reason that age 
at diagnosis was used here.  The age at diagnosis might be expected to be younger 
for a predominantly Black sample population as age of onset was reported to be 
younger internationally(6, 37).  This is likely to be explained by delayed presentation to 
the Connective Tissue Clinic at CHBAH either due to late presentation, or delays in 
referral due to failure by primary care practitioners to recognise features of 
connective tissue disease in younger patients.   
 
The majority of participants had dcSSc (62%) which is in keeping with reported rates 
of 50-70% in African Americans(6, 19) and 66% in Black South Africans(7), and 57-82% 
of Black Africans(8, 9).  In contrast, diffuse cutaneous disease is described in only 
37.1% of dominantly Caucasian patients in the EUSTAR cohort of 7655 scleroderma 
patients(40), which is a value consistent in the literature more generally where 30-40%  
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of Caucasian patients are reported to have dcSSc(5, 6, 19, 57).  The dcSSc subtype was 
more common amongst male participants (80% of the 19 male participants had 
dcSSc, and 60% of 132 female participants had dcSSc), although this was not 
statistically significant.  This may be a function of the fact that males were under-
represented in the sample population, and therefore the Gold-mining males may 
have skewed the male group towards the diffuse cutaneous disease subtype.   
 
Common clinical features of the overall sample population were Raynaud’s 
phenomenon (83%) and nailfold changes (70%).  Raynaud’s phenomenon has been 
reported more commonly in SSc participants (>95%) than has been found in this 
study(1), but it is a phenomenon that can be difficult to ascertain, especially in mild 
cases, and if there are language barriers as exists between patients and health care 
practitioners at CHBAH.  Additionally, it is a sign that is more difficult to appreciate in 
pigmented skin.  Nailfold changes reflect objective evidence of microvascular 
abnormalities with 70% of participants here demonstrating this sign.   
 
A positive ANA was found in 88% of the 151 participants.  A positive ANA has been 
reported in 75-95% of SSc patients in First World countries(27), with common patterns 
being nucleolar (anti-U3-RNP and RNAP I) and speckled (ATA, ACA, anti-U1-RNP, 
and RNAP-II and -III).  The proportions of these antibodies depend upon the clinical 
phenotype of the group studied. For example, ACA is more common in lcSSc (40-
60%) and Caucasian patients, and anti-U1-RNP and anti-U3-RNP are more common 
among African American SSc patients (6, 30).  The most common patterns found in 
this study were speckled (40.6%), nucleolar (31.6%) with ATA being the most 
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frequently measured specific autoantibody.  Anti-topoisomerase I antibody was 
present in only 18.8% of SSc patients in agreement with local studies(7) and in 
contrast to findings in the EUSTAR dominantly Caucasian cohort of 36.8%(40).  Anti-
centromere antibody was also quite uncommon with a rate of 7.5% amongst the 
ANA positive participants, which likely reflects the majority dcSSc disease subtype 
and Black ethnicity of this cohort.  Indeed only 1 of the 87 ANA positive dcSSc 
participants were ACA positive whereas 21.6% of the 37 ANA positive lcSSc 
participants were ACA positive. Conversely 24.4% of the ANA positive dcSSc 
participants were ATA positive and only 5.4% of the ANA positive lcSSc participants 
were ATA positive.  This significant association of ATA with dcSSc and ACA with 
lcSSC is consistent with published data (5, 6, 29, 58), however the number of lcSSc 
participants that were ACA positive is far fewer than reported in Caucasian dominant 
populations(1, 5, 19, 40), which is likely due to ethnic differences.  The nucleolar ANA 
was a common pattern, but it unfortunately cannot be subtyped at CHBAH.  One 
may suspect that it was contributed to by anti-U3-RNP, as this is a common antibody 
found in African American patients(30). 
 
There was a high percentage of participants (approximately 40%) lost to follow up, 
which does not allow for meaningful interpretation of survival data.  Some of these 
participants may have died, others may have defaulted follow up for any number of 
reasons.  There were 22 (15%) patients known to have died, which is comparable to 
previously local data where a 13% mortality rate was reported(7).  In 27.3% of 
patients known to have died in this study, there was insufficient information to 
ascertain cause of death.  In fact, there was only one documented post-mortem 
examination conducted where a cardiovascular cause of death was found.  The lack 
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of information in this regard may be explained by noting that in many South African 
cultures post mortems are not acceptable to family members.  From the data that 
does exist, ILD remains an important cause of death amongst the SSc patients at 
CHBAH, accounting for at least 18% of known deaths, and at least 44% of deaths in 
those with ILD.  Despite limitations in terms of numbers lost to follow up, this is 
comparable to international data where ILD accounted for 16% of overall deaths(59). 
 
4.2 Interstitial lung disease associations in systemic sclerosis 
 
Interstitial lung disease in this study was common (40%).  This is slightly lower than 
rates of ILD reported previously amongst African Americans internationally (46-
52%)(6, 37).  The slight difference in ILD rate may lie in method of diagnosis.  The 
rates in this study are however comparable to the EUSTAR database where 30-55% 
have been diagnosed with ILD by varying methods (40% by CXR, 32% by PFTs, 
52% by HRCT)(40).  With regard to disease subsets, in this study 52.1% of dcSSc 
patients developed ILD whereas 64% of dcSSc patients in the EUSTAR database 
developed ILD(40), which is comparable.  Meanwhile only 17.4% of lcSSc patients in 
this study developed ILD compared to 44% in the EUSTAR cohort(40).  The marked 
difference in proportions of lcSSc patients going on to develop ILD may be a function 
of cohort sizes (there are far more patients in the EUSTAR database), the lower 
proportion of lcSSc in this cohort (31% versus 59% in the EUSTAR database) likely 
due to ethnicity, and the lack of protective ACA in the lcSSc patients (and overall) in 
this study when compared to EUSTAR Caucasian predominant patients with lcSSc.  
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Of particular importance in this study was the comparative statistical association of 
SSc ILD with the following presentation features:  dcSSc, history of Gold-mining, 
cough, dyspnoea, and bibasal crackles.  Limited cutaneous SSc and ACA were 
associated with non-ILD participants.  Based on the 95% confidence intervals of 
odds ratios on multivariate analysis, disease duration (OR 1.19; 95% CI 1.09-1.30), 
bibasal crackles (OR 9.43; 95% CI 3.25-27.39), and speckled ANA (OR 1.22; 95% 
CI 1.22-7.15) all showed predictive relationships to SSc ILD.  As the 95% confidence 
intervals for the other variables (Gold-mining, cough, dyspnoea, disease subtype) all 
straddled unity, the odds ratios for these variables are of doubtful significance.  This 
is likely a function of the limited numbers of participants.  Although lcSSc was 
protective, the 95% confidence interval for the odds ratio for this variable crossed 
unity (OR 0.86; 95% CI 0.14-5.26).  Due to the zero frequency of ACA in the ILD 
group, odds ratios could not be calculated for this protective variable.  The generally 
wide confidence intervals are explained by the small numbers of participants for 
analysis.   
 
The SSc ILD disease process seems to be driven by dcSSc, not ATA, and as such a 
number of SSc ILD associations may be linked to the diffuse cutaneous subtype: 
 Participants with a Gold-mining history had a predominantly diffuse disease 
subtype (83.3%), and were almost six times more likely to develop ILD 
compared to those without a history of gold mining (OR 5.748, CI 95% 0.553-
59.754, p=0.037).    
 Diffuse cutaneous SSc itself was associated with SSc ILD (OR 2.257, CI 95% 
0.464-10.969, p<0.001).    
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 Diffuse cutaneous was significantly associated with Scl-70 antibodies.  These 
autoantibodies were not in turn associated with ILD, contrary to international 
data(6, 37). 
 Those ILD participants who had deceased had a higher rate of dcSSc 
compared to ILD participants who were alive (88.9% vs 80.8%, p=0.073), 
which trended towards significance. 
 
In terms of autoantibodies, a positive ANA trended towards significance in the ILD 
group, presumably due to a predominance of dcSSc in this group.  As far as 
scleroderma specific autoantibodies are concerned, an association that has 
previously been reported is between ATA and SSc ILD(7, 18, 58).  In this study ATA 
was more common in participants with ILD (22.8% versus 15.6% in the non-ILD 
group), but not significantly so.  Perhaps the lack of statistical significance was due 
to the limited numbers of participants, or it may be that this sample population is 
more comparable genetically to African American patients in Michigan where only 
22% of Black patients were found to be ATA positive(19).  Another possibility is that 
ATA is more associated with dcSSc, rather than ILD in this cohort of patients.  In 
support of this is the fact that 12 (24.5%) participants with dcSSc with ILD were ATA 
positive, and 9 (20.0%) participants with dcSSc without ILD were ATA positive.  Also 
more common in the ILD group was the speckled ANA pattern (50.9% in ILD group 
versus 32.9% in non-ILD group; p=0.010), which may in part be attributed to anti-U1-
RNP, more commonly found in African-Americans. 
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In contrast, ACA (0% in the ILD group versus 13.2% in the non-ILD group, p=0.006) 
and nucleolar-staining ANA patterns (22.8% in the ILD group versus 38.2% in the 
non-ILD group, p=ns) were less common in the ILD group.  In fact, ACA was not 
found in a single ILD participant.  Unlike with ATA, this does not seem to be a 
function of disease subtype in that none of the lcSSc participants with ILD (n=8) were 
ACA positive, whereas 8 (21.6%) of those lcSSc participants without ILD were ACA 
positive (p=ns).  As previously mentioned, nucleolar antibodies cannot be subtyped 
at CHBAH, so the contribution of RNAP and anti-U3-RNP could not be demonstrated 
in participants with this ANA pattern.  Interestingly, anti-U3-RNP has been shown to 
be more common in those with PAH, myositis and digital vasculopathy, and is more 
common in African American SSc patients(29, 30). 
 
4.3  Interstitial lung disease severity in systemic sclerosis 
 
The severity of ILD in this study was comparable to the spectrum of ILD seen in 
other studies, although there is some variation in the cut-offs used to define mild, 
moderate and severe ILD. The mild ILD participants represented 61.0% of the 59 
ILD patients with PFTs at baseline, 33.9% had moderate ILD, and 5.1% had severe 
ILD at presentation. In the Pittsburgh database of 890 SSc patients, mild ILD was 
defined as FVC>75% predicted, moderate as predicted FVC of 50-75%, and severe 
as predicted FVC≤50%.  Each category represented 60%, 27%, and 13% of ILD 
patients respectively(35).  The PFT cut-offs of 70% and 50% were used here to align 
with the Goh et al staging algorithm(41) (Figure 1.4.1).  Other data published uses 
HRCT grading systems, which was not possible here as none of the HRCT scans 
were graded in terms of severity of ILD.   
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Significantly more patients with moderate-severe ILD were diagnosed with ILD in the 
same year as SSc.  This may be considered compatible with data from Steen and 
Medsgar where the majority of severe SSc ILDs were diagnosed in the first 3 years 
of their SSc diagnosis(35).  It may, however, also be a function of late presentation, as 
well as those with more severe symptoms being fast-tracked for HRCT and PFTs. 
 
The presence of dyspnoea at presentation was found to be significantly associated 
with ILD disease severity (FVC<70% predicted, p=0.008).  These findings are 
consistent with previously reported international studies where cough was found to 
be a predictor of ILD activity and severity(51), and both dyspnoea and bibasal 
crackles were predictors of FVC decline in SSc ILD patients(52).    Unfortunately due 
to lack of data, particularly with respect to grading of ILD severity on HRCT, further 
associations were not amenable to analysis. 
 
4.4  Interstitial lung disease progression in systemic sclerosis 
 
Thirty nine (65.0%) out of the 60 ILD participants could be classified as having 
progressive ILD or non-progressive ILD based on PFTs at 6 months after SSc ILD 
diagnosis.  The minority of these 39 participants (23.1%) progressed at 6 months 
from baseline.  Those in the progressive ILD group demonstrated quite a dramatic 
decline in mean % predicted FVC (SD) over a 6 month period; from 80.8 (21.2) to 
63.4 (16.8).  Due to the lack of longitudinal data (6 month, 1 year, and 2 year PFTs) 
comparison with international literature is not possible.  Another unfortunate casualty 
of the lack of adequate longitudinal data is that the impact of any intervention 
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(increasing the dose of cyclophosphamide or lengthening the duration of treatment) 
for the progressive ILD participants instigated at 6 months upon viewing a decline in 
FVC could not be evaluated. 
 
There were no significant associations of baseline variables (demographic, clinical, 
or laboratory) with ILD disease progression, including baseline FVC.  The lack of any 
associations may be due to the lack of data in that there were very limited numbers 
of ILD participants where follow up PFTs were performed.  This was not done for 20 
of the ILD participants (33%) as the PFT machine at CHBAH was not functioning for 
a number of years in the past decade and participants were referred to neighbouring 
hospitals for PFTs.  Due to additional transport costs, and longer waiting lists due to 
increased strain on neighbouring hospitals’ PFT machines, many participants were 
unable to attend such appointments. 
 
In addition to missing data for PFTs, there was missing data for a number of baseline 
parameters.  The lack of recording of modified Rodnan skin scores rendered 
analysis of these parameters non-representative, but would have been of particular 
interest as association between Rodnan skin scores and ILD progression has been 
reported previously(52).   
 
4.5  Interstitial lung disease treatment in systemic sclerosis 
 
The median time (IQR) in years from diagnosis of SSc to diagnosis of SSc ILD was 0 
(1). This would suggest that most patients in this clinical setting were diagnosed with 
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SSc ILD at around the same time as first presentation to the Connective Tissue 
Diseases Clinic.  The median time (IQR) in months from ILD diagnosis to ILD 
treatment was 1 (3), which reflects a prompt initiation of treatment within the 
department.  The results were somewhat skewed by the 10 individuals who were 
started on immunosuppression (predominantly corticosteroids) prior to diagnosis of 
ILD.  However there appears to be a similar counter effect whereby a single 
participant was started on treatment 85 months after ILD diagnosis as it was not until 
this late stage that he became symptomatic of ILD and showed changes on HRCT 
amenable to treatment.   
 
Overall, approximately 85% of ILD participants received treatment with 
immunosuppression.  The most frequently used medications were intravenous 
cyclophosphamide and corticosteroids.  More of this regime was used in the non-
progressive ILD group compared to the progressive ILD, but this was not statistically 
significant.   The only significant difference shown in different treatment groups was 
an association between non-progressive ILD and the use of D-penicillamine (16.7% 
versus 11.1% in progressive ILD, p=0.043).  This is consistent with data from 
Pittsburgh in 1985(60) where the use of D-penicillamine for SSc ILD was found to 
improve DLCO significantly, with no progression of dyspnoea symptoms.  This  was 
confirmed in 1987 in a smaller study by de Clerck et al(61), and more recently by Derk 
et al in 2001(62).    
 
Complications occurring during treatment were restricted to 4 ILD participants 
(6.6%), and included infections (tuberculous and non-tuberculous), as well as 
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haemorrhagic cystitis from cyclophosphamide administration.  This would be judged 
by most clinicians a good complication profile, although other side effects of 
medications reported by patients were not recorded in this study. 
 
4.6  Interstitial lung disease survival in systemic sclerosis 
 
There was no significant difference between ILD and non-ILD mortality rates (both 
approximately 15%).  This may be due to the poor follow up rate, whereby about 
40% of participants in each group were lost to follow up.  The percentage of 
participants who died in the two ILD severity groups were similar (13.0% in the 
FVC<70% group versus 16.7% in the FVC≥70% group; p=ns).  However, the 
percentage of participants who died in the progressive ILD group was greater 
compared to the non-progressive ILD group (33.3% versus 10.0%; p=ns).  The lack 
of significance may lie in the small number of participants in these latter subgroups. 
 
Associations with SSc ILD participant mortality were hampered by the low numbers 
of participants for whom this outcome was known.  The high numbers of participants 
lost to follow up renders analysis, and application of this analysis difficult.  Despite 
this, bibasal crackles was significantly associated with mortality in the ILD group 
(p=0.014), as were raised plasma urea (p=0.041) and reduced serum albumin 
(p=0.007).  Interestingly, disease duration was shorter in those SSc ILD participants 
who had deceased compared to those that were alive (2.0 versus 7.0 years; 
p<0.0001).  This would suggest those with a more aggressive ILD tended to develop 
ILD earlier in their SSc disease process.  These findings are in keeping with those of 
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Steen and Medsger (2012)(36) who reported that 45-55% of severe ILD occurred in 
the first 3 years of SSc diagnosis.   Proximal weakness and telangiectasia were 
significantly associated with ILD alive participants.  This may reflect a tendency in 
these participants to muscle and vascular complications (as associated with 
nucleolar ANA pattern) rather than severe or progressive ILD.  
 
The significantly lower mean serum albumin in the ILD deceased group (34.0 g/l 
versus 39.1 g/l, p=0.007) may be as a result of proteinuria from the vasculopathy at a 
renal level (raised plasma urea may also be related to this).  Only 3 participants had 
SRC but many more likely had proteinuria, which is known to predict mortality in 
SSc(59).  Another possibility is that a low serum albumin may reflect persistent active 
inflammation in a more aggressive disease process.   In support of this is the trend 
whereby the baseline median CRP was higher in ILD participants who deceased (9.2 
mg/l vs 6.0 mg/l; p=0.066), and a higher proportion of participants in the deceased 
group had a CRP>8 mg/l (66.7% versus 33.3%; p=0.065).  This is in keeping with 
findings where CRP>8mg/l was associated with mortality in SSc ILD patients(53, 54).  
The limited number of participants unfortunately limited these results, added to which 
14.3% participants were missing CRP.    
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CHAPTER FIVE:  CONCLUSIONS AND FUTURE DIRECTIONS 
 
The most important findings from this study are those that are applicable to clinical 
practice in South Africa.  Namely, all of the baseline history and examination features 
associated with and predictive of SSc ILD are those that a junior doctor could elicit 
from a patient in a non-specialist clinic.  As such, a patient meeting the diagnostic 
criteria for SSc (particularly dcSSc) who presents with one or more of these features 
(history of gold-mining, dyspnoea, cough, bibasal crackles), should be referred for 
investigations of SSc ILD (PFTs and HRCT), and a referral made to a rheumatologist 
for further, timeous management.  
 
These findings were despite limitations of participant numbers and missing data.  
The limited number of participants made analysis and application of that analysis 
difficult, particularly with respect to disease severity, disease progression, disease 
treatment, and survival.  Systemic sclerosis is a rare disease and thus sufficient data 
will always be a challenge.  One way this may be generally improved in order to 
strengthen the findings of this study is to include data from multiple sites.  In this 
manner other referral centre data could be combined with this data to consolidate 
current results.  Additionally, investigation into why so many patients are lost to 
follow up should be conducted so that this issue can be addressed.  An education 
programme for patients with group sessions to reinforce information given in doctor 
consultations, to address compliance problems, and to provide social support may 
be of benefit. 
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In terms of data missing from presentation visits, and information missing from 
follow-up investigations, this may be due to a number of different factors.  There is a 
very busy clinic environment at CHBAH which may lead to information not being 
documented due to time pressures.  One way this may be addressed is to use pro-
forma clerking sheets and “tick-box” inserts in patient files to serve as reminders as 
when to order specific investigations, with regular audit.  This would also assist the 
more junior members of staff who rotate through the department every four months.  
It would provide additional guidance for them to that already provided from senior 
staff members in contributing to the overall patient management timeline.  To this 
end, updated patient summaries placed in the front of all patient files may also be 
helpful.  Additionally, pre-filled investigation forms where the patient details alone 
need to be added may expedite patient visits, or indeed a paperless system would 
also achieve this, although this would be difficult to initiate and maintain in the 
current environment.  Another factor is equipment failure from blood pressure cuffs, 
weight scales, laboratory services, to radiology and lung function facilities.  
Investigation into why this occurs needs to commence, and regular maintenance 
occur.   
 
Although SSc ILD is a rare disease in the general population, the morbidity and 
mortality caused to those affected is marked.  This study has shown that in this 
cohort of patients, the diffuse cutaneous disease subtype seems to be the main 
driver behind the development of ILD, not autoantibodies.  Not all dcSSc patients 
develop ILD and there are some ILD patients that have lcSSc.  Anti-centromere 
antibodies are protective for ILD, and the lack of ACA in Black patients might 
contribute to the development of ILD in this cohort compared to the international 
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literature.  Contributions from genetic factors remain unelucidated however, and in 
terms of furthering this body of work, not just consolidating it, this is an important 
area for future study. 
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APPENDIX A: Preliminary classification criteria for systemic 
sclerosis(55) 
 
One major criterion or two minor criteria. 
Major Criterion: 
 Proximal scleroderma 
Minor Criteria: 
 Sclerodactyly 
 Digital pitting, or scars, or loss of substance from finger pad 
 Bibasilar pulmonary fibrosis  
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APPENDIX B:  Data collection sheet 
 
Participant study number: _____________        Date of 1st visit:____________ 
Date of last visit: ___________ 
Demographics 
Age: ____________   
Gender:   
 
Ethnicity:  
 
 YES NO DETAILS 
Mining exposure    
Toxin exposure    
Current occupation    
 
 Yes No  Number/day Years Years 
stopped Smoker 
 
  If yes   
Ex-
smoker 
  If yes    
 
 
Date of onset of first non-Raynaud’s symptom: __________________ 
Disease duration: ___________________ 
Age at onset: _______________________ 
Age at diagnosis:____________________ 
History 
 YES NO DATE OF 
ONSET 
DETAILS 
Raynaud’s     
Reflux/Dysphagia     
Myalgia/weakness     
Arthritis/arthralgia     
Dyspnoea    NYHA class: 
Cough     
Tightening of skin 
on hands/face 
    
 
M F 
B W C I O 
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Other medical History: 
 Yes No Date of onset Details 
HIV     
TB     
 
Examination 
ACR criteria fulfilled:              
Disease subset: Diffuse Limited Unclassified 
Weight: ______ kg 
Pulse rate: _____ /min  regular/ irregular 
Blood pressure: ____ /_____ 
Maximum modified Rodnan Skin score: _______ 
 YES NO DETAILS 
Sclerodema    
Digital scars    
Digital ulcers active    
Digital gangrene    
Nailfold changes    
  Telangiectasia    
Calcinosis    
Arthritis    
Tendon friction rubs    
Proximal Myopathy    
SRC    
 
Breath sounds: 
 Yes No 
Normal   
Crackles – 
basal 
  
Crackles – 
Diffuse 
  
Wheezes   
 
Clubbing: Y N 
 
Requires oxygen: Y N 
 
Y N 
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Investigations 
Urinalysis: 
 Yes No 
Dipstix 1+ protein   
Dipstix 2+ protein   
Dipstix 3+ protein   
Urine PCR  
 
ECG: 
 YES NO DETAILS 
Arrythmias    
Conduction block    
 
Echo: 
 YES NO  
Pulmonary 
hypertension 
  If yes, PAPsys =  
Pericardial effusion    
LVEF% =     
 
 
ILD: Y N 
 
Date ILD 
diagnosis: 
   
 YES NO Date 
Velcro crackles    
CXR fibrosis    
HRCT    
PFT    
 
CXR: 
 Yes No Date 
Normal    
Fibrosis    
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HRCT: (at diagnosis) 
 Yes No 
Normal   
Ground glass   
Honeycombing   
Fibrosis   
PAH   
 
PFT at diagnosis: 
  
 
  YES NO 
TLC (% pred)   Restrictive   
FEV1 (% pred)   FVC > 70%   
FVC (% pred)   FVC 50 – 69%   
DLCO (% 
pred) 
  FVC < 50%   
 
Barium swallow: 
Date    
 YES NO Details 
Oesophageal reflux    
Oesophageal dysmotility    
 
Laboratory: 
ANA titre  CRP  
Centromere  ESR  
Speckled  C3  
Nucleolar  C4  
Homogenous  Hb  
Ds DNA  MCV  
Sm  HCT  
Ro  WCC  
La  Neuts  
RNP  Lymphs  
RF  Eos  
Scl-70  Na  
Lupus anticoagulant  K  
IgM anticardiolipin  urea  
IgG anticardiolipin  creat  
TChol  CK  
LDH  alb  
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Treatment 
 Route Dose Start date Stop date Details 
Steroids                  mg/d    
Cyclophos             mg/4 wks    
Methotrexate                  mg/wk    
Azathioprine                  mg/d    
MMF                  mg/d    
Iloprost      
PPI      
Nifedipine      
ACE-i/ARB      
Statin      
Aspirin      
 
 
POST TREATMENT FOLLOW-UP PFT 
 
 6 months 12 months 24 months 
TLC    
FEV1    
FVC    
FEV1/FVC    
DLCO    
 
SURVIVAL DATA 
 YES NO DATE 
DECEASED    
ALIVE    
LOST TO 
FOLLOW 
UP 
   
 
 YES NO 
Infection   
Malignancy   
ILD   
CVS   
Renal   
Other   
 
67 
 
APPENDIX C:  Ethical Approval Certificate 
 
 
